Your browser doesn't support javascript.
loading
Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas.
Remacha, Laura; Comino-Méndez, Iñaki; Richter, Susan; Contreras, Laura; Currás-Freixes, María; Pita, Guillermo; Letón, Rocío; Galarreta, Antonio; Torres-Pérez, Rafael; Honrado, Emiliano; Jiménez, Scherezade; Maestre, Lorena; Moran, Sebastian; Esteller, Manel; Satrústegui, Jorgina; Eisenhofer, Graeme; Robledo, Mercedes; Cascón, Alberto.
Affiliation
  • Remacha L; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Comino-Méndez I; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Richter S; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Contreras L; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
  • Currás-Freixes M; Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
  • Pita G; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Letón R; Human Genotyping Unit-CeGen, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Galarreta A; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Torres-Pérez R; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Honrado E; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Jiménez S; Anatomical Pathology Service, Hospital de León, León, Spain.
  • Maestre L; Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Moran S; Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Esteller M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.
  • Satrústegui J; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.
  • Eisenhofer G; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
  • Robledo M; Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid and Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain.
  • Cascón A; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Clin Cancer Res ; 23(20): 6315-6324, 2017 Oct 15.
Article in En | MEDLINE | ID: mdl-28720665

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Paraganglioma / Pheochromocytoma / Citric Acid Cycle / Genetic Predisposition to Disease / High-Throughput Nucleotide Sequencing / Exome / Mutation Type of study: Prognostic_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2017 Document type: Article Affiliation country: España Country of publication: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Paraganglioma / Pheochromocytoma / Citric Acid Cycle / Genetic Predisposition to Disease / High-Throughput Nucleotide Sequencing / Exome / Mutation Type of study: Prognostic_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2017 Document type: Article Affiliation country: España Country of publication: Estados Unidos